University of Malta
 

Variations in SmPC of local medicinal products
UOM Main Page
 
 
 
Apply - Admissions 2016
Newspoint
Malta Medical Journal
MPS

 

Variations in summary of product characteristics of medicinal products available locally

From January till June 2011, the following variations (Type II) have been included in the summary of product characteristics of medicinal products available locally as accepted by the European Medicines Agency.

For further information, kindly click on the respective proprietary name.

 
Cardiovascular system

Rasilez®
Revatio®
Tredaptive®
Xarelto®

Central Nervous System

Champix®
Exelon®
Invega®
Lyrica®
Valdoxan®

Infections

Doribax®
KaletraTM
Tamiflu®

Endocrine system

Aclasta®
Eucreas®
Fosavance®
Galvus®
Protelos®
Zometa®

Obstetrics, gynaecology,
and urinary tract disorders

Levitra®
Toviaz®

Malignant disease and
immunosuppression

Afinitor®
Glivec®
Nexavar®
Revlimid®
Simulect®
Tysabri®
Tyverb®

Musculoskeletal and
joint diseases
Humira®

EyeLucentisTM

Skin

Altargo®
Protopic®

Immunological products
and vaccines

Cervarix®
Pandemrix®
Rotarix®
Twinrix Adult®
Synflorix®

AnaesthesiaDynastatTM
Calendar
Notices
Pharm.D. Programme

Postgraduate Programme leading to Doctorate in Pharmacy 

Read more here

 
 

Log In back to UoM Homepage